The regulatory and supply landscape for retatrutide and semaglutide could not be more different right now, and these practical realities will determine which option is available to most people for the foreseeable future
The Danish diabetes and obesity giant Novo Nordisks (NOV: N) GLP-1 receptor agonist is already approved for use in the treatment of obesity and for weight management, to be used alongside diet, physical activity and behavioural support
GIP activation appears to complement GLP-1 effects synergistically rather than additively, which explains why Tirzepatide (dual agonist) produces significantly more weight loss than Semaglutide (single agonist) despite both activating GLP-1
Oddway International supports wholesale procurement for importers and distributors, subject to local regulations and product classification in your country
Blind testing like that, he told one interviewer, is whats actually keeping everyone in check, including us. Rory Hester, who covers the scene and recently co-founded a peptide company himself, told Zhang the line I cant stop thinking about: The future of the market is normies. Your grandmother wont use Telegram
GLP-1s Associated with Reduced Asthma Exacerbation in Patients Without Diabetes
